Molecular Cancer Therapeutics · 2006 · 162 citations · 59 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyStructure-activity RelationshipsEnzyme InhibitionLigand BindingTopoisomerase InhibitorsBase Pairing Hydrogen BondsCatalytic Cycle ConformationsCovalent Drug BindingDna Topoisomerase I InhibitionProtein-drug BindingTopoisomerase ActivityTopoisomerase I InhibitorsUncompetitive Inhibition
We show that five topoisomerase I inhibitors (two indenoisoquinolines, two camptothecins, and one indolocarbazole) each intercalate between the base pairs flanking the cleavage site generated during the topoisomerase I catalytic cycle and are further stabilized by a network of hydrogen bonds with topoisomerase I. The interfacial inhibition paradigm described for topoisomerase I inhibitors can be generalized to a variety of natural products that trap macromolecular complexes as they undergo catalytic conformational changes that create hotspots for drug binding. Stabilization of such conformational states results in uncompetitive inhibition and exemplifies the relevance of screening for ligands and drugs that stabilize ("trap") these macromolecular complexes.
59